Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH17626FSA
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Zogenix Inc (ZGNX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company's lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS). ZX008 is in Phase 3 clinical trials and has orphan drug designation in the US and EU and secured Fast Track designation and breakthrough therapy designation from the US FDA. The company operates in the UK through its subsidiary Zogenix International, Ltd. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc Key Recent Developments

Sep 04,2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare-GNW RSS]

Aug 30,2018: Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology

Aug 06,2018: Zogenix provides corporate update and reports second quarter financial results

Jul 02,2018: Zogenix Appoints Ashish Sagrolikar As New Global Chief Commercial Officer

May 09,2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Zogenix Inc-Key Facts 6

Zogenix Inc-Key Employees 7

Zogenix Inc-Key Employee Biographies 8

Zogenix Inc-Major Products and Services 9

Zogenix Inc-History 10

Zogenix Inc-Company Statement 11

Zogenix Inc-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Company Overview 14

Zogenix Inc-Business Description 15

R&D Overview 15

Zogenix Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

Zogenix Inc-Strengths 16

Zogenix Inc-Weaknesses 17

Zogenix Inc-Opportunities 18

Zogenix Inc-Threats 19

Zogenix Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Zogenix Inc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare-GNW RSS] 31

Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare-GNW RSS] 35

Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare-GNW RSS] 39

Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results 43

May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results 45

Mar 06, 2018: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 47

Nov 07, 2017: Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results 49

Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results 51

May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 53

May 04, 2017: Zogenix Q1 net loss increases 54

Section 6-Appendix 55

Methodology 55

Ratio Definitions 55

About GlobalData 59

Contact Us 59

Disclaimer 59

List of Figures

Zogenix Inc, Performance Chart (2013-2017) 25

Zogenix Inc, Ratio Charts 27

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

List of Tables

Zogenix Inc, Key Facts 6

Zogenix Inc, Key Employees 7

Zogenix Inc, Key Employee Biographies 8

Zogenix Inc, Major Products and Services 9

Zogenix Inc, History 10

Zogenix Inc, Other Locations 13

Zogenix Inc, Subsidiaries 13

Zogenix Inc, Key Competitors 20

Zogenix Inc, Ratios based on current share price 21

Zogenix Inc, Annual Ratios 22

Zogenix Inc, Annual Ratios (Cont...1) 23

Zogenix Inc, Annual Ratios (Cont...2) 24

Zogenix Inc, Interim Ratios 26

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Zogenix Inc, Recent Deals Summary 30

Currency Codes 55

Capital Market Ratios 55

Equity Ratios 56

Profitability Ratios 56

Cost Ratios 57

Liquidity Ratios 57

Leverage Ratios 58

Efficiency Ratios 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Xenon Pharmaceuticals Inc

GW Pharmaceuticals Plc

Biocodex

Amorsa Therapeutics Inc

Acadia Pharmaceuticals Inc

Zogenix Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8651
Site License
USD 250 INR 17303
Corporate User License
USD 375 INR 25954

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com